Catalyst Dossier · compiled by CeliA 🧫
Cosmo Pharmaceuticals N.V. (COPN.SW)
Pharmaceutical Preparations · market cap $1.2B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Cosmo Pharmaceuticals N.V. (COPN.SW) is a Swiss-listed specialty pharma company with 324 employees and a market cap of approximately $1.24B. Its pipeline is centered on two platform technologies — Rifamycin SV MMX and Methylene Blue MMX — spanning gastrointestinal infection, IBS, colon staining, and colorectal cancer detection, with the lead asset (Rifamycin SV MMX for Traveler's Diarrhea) in Phase 3. No near-term catalysts are currently scheduled on the public calendar.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rifamycin SV MMX | Phase 3 | Traveler's Diarrhea |
| 400 mg Rifamycin SV dosage | Phase 2 | Infectious Diarrhoea |
| Rifamycin SV 600mg t.i.d. | Phase 2 | Diarrhea-predominant Irritable Bowel Syndrome |
| Methylene Blue MMX tablets | Phase 2 | Colorectal Cancer |
| Methylene Blue MMX® | Phase 3 | Colorectal Cancer |
| Methylene Blue MMX 25 mg modified release tablets | Phase 2 | Colon Staining in Preparation for Colonoscopy |
| Budesonide | Phase 3 | Colitis, Ulcerative |
| Budesonide MMX® 6 mg | Phase 3 | Ulcerative Colitis |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for COPN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.